Last reviewed · How we verify

NCT04086836: SWESTAT

Swedish Study on STroke After TAVR

Completed Last updated 6 April 2020
What this trial tests

trial testing TAVR in Aortic Valve Disease in 4,600 participants. Completed in 1 February 2020.

Timeline
1 July 2019
Primary endpoint
1 February 2020
1 February 2020

Quick facts

Lead sponsorRegion Skane
StatusCompleted
Study typeOBSERVATIONAL
Enrollment4,600
Start date1 July 2019
Primary completion1 February 2020
Estimated completion1 February 2020
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Region Skane — full company profile →

Who can join

Eligibility, any sex, with Aortic Valve Disease or Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims at studying the frequency of late stroke after transcatheter aortic valve replacement/implantation

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Late stroke after transcatheter aortic valve replacement: a nationwide study.
    Bjursten H, Norrving B, Ragnarsson S. · · 2021 · cited 23× · PMID 33953339 · DOI 10.1038/s41598-021-89217-0

Verify or expand the search:

Other trials of TAVR

Trials testing the same drug.

Other recruiting trials for Aortic Valve Disease

Currently open trials in the same condition.

Other Region Skane trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04086836.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing